{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:36:38Z","timestamp":1773221798944,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T00:00:00Z","timestamp":1498262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.jmii.2017.06.005","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T23:48:04Z","timestamp":1498693684000},"page":"473-477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Meropenem versus piperacillin\/tazobactam with or without immunoglobulin as second-line therapy for febrile neutropenia\u00a0in pediatric patients"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3937-0856","authenticated-orcid":false,"given":"Ryoji","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Hori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirozumi","family":"Sano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2017.06.005_bib1","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1046\/j.1365-2141.1997.4453255.x","volume":"99","author":"Hann","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jmii.2017.06.005_bib2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/clinids\/13.3.397","article-title":"Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer","volume":"13","author":"Viscoli","year":"1991","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.jmii.2017.06.005_bib3","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2017.06.005_bib4","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/ped.12279","article-title":"Effect of meropenem with or without immunoglobulin as second-line therapy for febrile neutropenia in pediatric patients","volume":"56","author":"Kobayashi","year":"2014","journal-title":"Pediatr Int"},{"key":"10.1016\/j.jmii.2017.06.005_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26360","article-title":"A prospective randomized trial comparing piperacillin\/tazobactam with meropenem as empiric antibiotic treatment of febrile neutropenic children and adolescents with hematologic and malignant disorders","volume":"64","author":"Sano","year":"2017","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1016\/j.jmii.2017.06.005_bib6","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.jmii.2017.06.005_bib7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1023\/A:1009899803032","article-title":"Structure and function of immunoglobulin","volume":"3","author":"Spath","year":"1999","journal-title":"Sepsis"},{"key":"10.1016\/j.jmii.2017.06.005_bib8","first-page":"605","article-title":"Intravenous immunoglobulin","volume":"vol. 3","author":"Bittner","year":"2007"},{"key":"10.1016\/j.jmii.2017.06.005_bib9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s12016-009-8153-y","article-title":"High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases","volume":"38","author":"Ishii","year":"2009","journal-title":"Clin Rev Allerge Immunol"},{"key":"10.1016\/j.jmii.2017.06.005_bib10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s10067-004-0959-7","article-title":"Efficacy of intravenous immunoglobulin in chronic idiopathic pericarditis: report of four cases","volume":"24","author":"Peterlana","year":"2005","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jmii.2017.06.005_bib11","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1023\/A:1021481122011","article-title":"Locally delivered polyclonal antibodies potentiate intravenous antibiotic efficacy against gram-negative infections","volume":"19","author":"Barekzi","year":"2002","journal-title":"Pharm Res"},{"key":"10.1016\/j.jmii.2017.06.005_bib12","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s10096-013-1861-5","article-title":"Assessment of the efficacy of polyclonal intravenous immunoglobulin G (IVIG) against the infectivity of clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) in\u00a0vitro and in\u00a0vivo","volume":"32","author":"Farag","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jmii.2017.06.005_bib13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1189\/jlb.4A0813-422RRR","article-title":"Enhancement of neutrophil autophagy by an IVIG preparation against multidrug-resistant bacteria as well as drug-sensitive strains","volume":"98","author":"Itoh","year":"2015","journal-title":"J Leukoc Biol"},{"issue":"464","key":"10.1016\/j.jmii.2017.06.005_bib14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbrc.2015.06.004","article-title":"Intravenous immunoglobulin enhances the killing activity and autophagy of neutrophils isolated from immunocompromised patients against multidrug-resistant bacteria","volume":"14","author":"Matsuo","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jmii.2017.06.005_bib15","first-page":"199","article-title":"The efficacy of intravenous immunoglobulin in combination therapy with antibiotics for severe infections","volume":"48","author":"Masaoka","year":"2000","journal-title":"Jpn J Chemother"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S168411821730107X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S168411821730107X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:22:00Z","timestamp":1761657720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S168411821730107X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S168411821730107X"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2017.06.005","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meropenem versus piperacillin\/tazobactam with or without immunoglobulin as second-line therapy for febrile neutropenia\u00a0in pediatric patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2017.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}